NCT00165841

Maintenance Intermittent Therapy for Symptomatic GERD Patients

A Double-Blind, Placebo-Controlled Study of Rabeprazole 20 mg Maintenance Intermittent Therapy Following Acute Treatment in Patients Wth Symptomatic Gastroesophageal Reflux Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).

Conditions

• Gastroesophageal Reflux Disease

Interventions

Type	Name	Description
DRUG	Rabeprazole 20 mg	rabeprazole sodium tablet 20 mg once daily

Timeline

• Start date: 2004-10-01
• Primary completion: 2005-12-01
• Completion: 2008-06-01
• First posted: 2005-09-14
• Last updated: 2013-05-20
• Results posted: 2009-12-03

Locations

1 site across 1 country: United States